Oslo, 04. April 2016. Serodus ASA (OAX:SER) today announce that the company has initiated work to evaluate the company's financing alternatives as part of planning a further development of the lead projects to next development stages - which also goes beyond the end of 2016.

'Serodus are currently in an interesting stage of the development with a lead program about to complete phase 2a halting the progression of patients with Diabetic Nephropathy, an indication attractive to both investors and the pharmaceutical industry. The company which to continue the development into the next development stage, as this will create significant shareholders value provided the expected positive outcome.' said CEO Eva Steiness.

Consequently, the Board of Directors has decided to initiate work on evaluating the company's capital need and financing alternatives to progress development of its lead candidates and reach further milestones and value inflection points. Norne Securities has been retained as financial advisors in connection with this evaluation.

For more information contact:

Tore Kvam

CFO and IR, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a drug development company listed on Oslo Stock Exchange, focusing on new therapeutic products for the treatment of metabolic and cardiovascular diseases with large unmet clinical needs. The company's business model is to in-license drug candidates from universities and biotech companies, mature the compounds and seek partnering with international pharmaceutical companies before Phase 3. For more information see www.serodus.com.

Serodus ASA issued this content on 07 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 07 April 2016 10:12:09 UTC

Original Document: http://www.serodus.com/News/2016/Serodus-to-evaluate-financing-options-for-lead-programs